2020-05-28 17:25 ET - News Release
Mr. Paul Woodward reports
ADVANCED PROTEOME THERAPEUTICS ANNOUNCES FIRST RESULTS OF PILOT PROJECT
Advanced Proteome Therapeutics Corp.'s U.S. subsidiary, Advanced Proteome Therapeutics Inc. (APTI), has received the first results as part of its collaborative pilot project with a promising Boston-based biotechnology company (Biotech), as announced on Feb. 10, 2020. The pilot project is testing APTI's site-specific conjugation technology with Biotech's proprietary antibody against a high-value target.
APTI's antibody-drug conjugate (ADC) construct was compared with an ADC construct using the same antibody, toxin and drug to antibody ratio, but an alternative conjugation technology. In cell culture studies conducted by Biotech, APTI's ADC demonstrated over 15 times greater potency than the comparator ADC. Based on these results, further studies are planned in different models. These further studies are expected to take place upon the reopening of the two companies' laboratories in Boston.
Dr. Benjamin Krantz, director of APTI, commented: "This is a fantastic result which shows greater potency of the ADC utilizing APT's site-specific, homogeneous conjugation technology in this in vitro model. This is particularly exciting because we expect the most significant benefits from APT's ADC conjugation technology to be in vivo, where ADC stability and activity are challenged under physiologic conditions. We look forward to continuing this collaboration and development of this promising ADC."
Terms of any agreement are to be finalized after pilot completion. The antibody is directed at a highly attractive target that has yet to be successfully addressed. It is overexpressed in up to 90 per cent of malignancies including breast, lung, pancreas, colon and many others. Biotech's in-depth understanding of the target biology has enabled the targeting of a unique portion that overcomes the limitations of previous strategies. Prior preclinical study has demonstrated that both the antibody and the target have the appropriate characteristics and therefore substantial promise for ADC therapies.
Paul Woodward, chief executive officer of Advanced Proteome, said, "This result is another step on the road to proving that APTI's technology is the gold standard of conjugation technologies, technology that will enable the creation of safer and more efficacious ADC therapeutics for patients."
About Advanced Proteome Therapeutics Corp.
Advanced Proteome, through its subsidiary, APTI, has invented proprietary protein conjugation technology that enables the development of superior antibody-drug conjugates through improved site-specific labelling, drug-antibody ratio control and the enabling of combination payloads. The technology has compelling preclinical data demonstrating improved homogeneity and increased in vivo potency relative to current state-of-the-art linker technology. The company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics, and is pursuing licensing and partnership opportunities to advance development and create shareholder value.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.